Forge Enters Into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections
Forge is eligible to receive $190.5M in total payments SAN DIEGO, California, March 25, 2020 – Forge Therapeutics, Inc. (Forge) announced today that ...
Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections
-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform- San Diego, California, Aug 14, 2019 – Forge Therapeutics, Inc. (Forge), a ...